Dongsheng Chiral Pharma

News

Dongsheng Chiral invested in a small molecule R&D service center in Western Medicine Valley of Lanzhou to accelerate the R&D process of small molecule drugs from innovative ideas to the pre-clinical stage in Greater China and enhance our CDMO service

Addtime：2018-10-10

On October 10, 2018, the core leadership of Dongsheng Chiral decided to start the construction of a domestic first-class integrated R&D service center for small molecule chemical drugs in Western Medicine Valley of Lanzhou, aiming to provide complete solutions for domestic small molecule chemical drug discovery and development and to provide one-stop services for promoting small molecule chemical drug R&D from innovative ideas to pre-clinical. The Lanzhou R&D center is expected to be operational in the third quarter of 2022.

图片10.png